Halozyme Therapeutics

Halozyme Therapeutics is a biopharmaceutical company dedicated to the development of products targeting the extracellular matrix for the insulin, cancer, dermatology, and drug delivery markets. The company's product portfolio is primarily based on intellectual property covering a series of human enzymes known as hyaluronidases and other enzymes that affect the extracellular matrix. Halozyme’s Enhanze™ technology is an innovative drug delivery platform designed to enhance the absorption and dispersion of biologics. The company has established significant partnerships with Roche, Baxter, ViroPharma, and Intrexon to apply the Enhanze technology to therapeutic biologics, including Herceptin®, MabThera®, immunoglobulins, Cinryze®, and alpha1-antitrypsin.